Fagron Recalls Estrone Compounding Powder Due to Quality Assurance Deviations
Fagron, Inc. is recalling Estrone for Prescription Compounding due to lack of quality assurance at the API manufacturer.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a reasonable probability of temporary or medically reversible health consequences. The source text does not report any illnesses or injuries, and the hazard is a manufacturing deviation rather than a confirmed contamination or defect causing immediate harm.
Plain-English summary
Fagron, Inc. is recalling Estrone, For Prescription Compounding, which is distributed in 1 g, 5 g, 25 g, and 100 g bottles. The product is also distributed by Freedom under the name Estrone USP, For Prescription Compounding, in the same bottle sizes. The recall involves a total of 1,313 grams of the product.
The recall was initiated due to Current Good Manufacturing Practice (cGMP) deviations, specifically a lack of quality assurance at the active pharmaceutical ingredient (API) manufacturer. The affected lots are distributed nationwide in the US and Puerto Rico, as well as in Australia.
Consumers and healthcare providers should stop using the recalled product and contact Fagron, Inc. or Freedom for further instructions. The specific lot numbers and expiration dates are listed in the official recall documentation.
The recalled product
- Product
- Estrone, For Prescription Compounding, packaged in a) 1 G bottle (NDC: 51552-0445-1), b) 5 G bottle (NDC 51552-0445-2), c) 25 G bottle (NDC: 51552-0445-4), d) 100 G bottle (NDC: 51552-0445-5), RX only, Distributed by Fagron, Inc. 2400 Pilot Knob Rd, St. Paul, MN 55120 Tel. 1-(8
- Manufacturer
- Fagron, Inc
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (17)
- Lot #
- Expiration Date: a) 16J05-U01-032346
- 16G18-F003A
- Exp. 5/17/2018
- 16J25-U05-033898
- Exp. 5/18/2018. b) 16F23-U04-031011
- 16J05-U02-032345
- 16J25-U05-033897
- 16J25-U05-034708
- 16J25-U05-035527
- Exp. 5/18/2018
- c) 16F23-U04-031024
- 16K16-U337-033665
- 16G18-F003
- Exp. 5/17/2018. d) 16K16-U337-033664
- 16J25-U05-034707
- Exp. 5/18/2018.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Fagron, Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Fagron, Inc
See all →- HighNystatin Bulk Powder Recall for Incorrect Label Assay Value
FDA (Drugs) · 2023-12-27
- HighNystatin Powder Recall Due to Incorrect Assay Strength on Label
FDA (Drugs) · 2023-12-27
- HighNystatin bulk powder recall due to incorrect assay strength label
FDA (Drugs) · 2023-12-27
- HighNystatin Bulk Powder Recalled Due to Incorrect Label Strength
FDA (Drugs) · 2023-12-27
- SevereSyrSpend SF Suspending Base Recalled for Burkholderia Contamination
FDA (Drugs) · 2022-05-18
Same hazard · quality assurance
See all →- HighSucralfate tablets recalled after bankruptcy left quality program unmonitored
FDA (Drugs) · 2025-09-03
- ModerateSucralfate tablets recalled because bankruptcy left the quality program unmonitored
FDA (Drugs) · 2025-08-06
- ModerateLidoPatch Pain Relief Patches Recalled Due to Missing Manufacturing Records
FDA (Drugs) · 2020-06-03
- ModerateMedtech Recalls Clear Eyes Maximum Itchy Eye Relief Due to Quality Concerns
FDA (Drugs) · 2019-08-28
- ModerateMedtech Recalls Clear Eyes Maximum Itchy Eye Relief Drops
FDA (Drugs) · 2019-08-28